Skip to Main Content
Table 2—

Baseline demographics and characteristics and baseline to end point changes in the glycemic control variables of the analysis population

Insulin glargineNPH insulin
Sex   
    Men 636 (56) 652 (56) 
    Women 506 (44) 510 (44) 
Age (years) 58.0 ± 9.8 58.4 ± 9.3 
BMI (kg/m230.5 ± 4.9 30.5 ± 6.4 
Age at onset of diabetes (years) 48.4 ± 9.7 48.4 ± 9.7 
Diabetes duration (years) 10.2 ± 7.0 10.6 ± 6.9 
Type of previous treatment   
    OAD only 815 (71) 826 (71) 
    Insulin only 259 (23) 259 (22) 
Duration of insulin treatment (years)* 7.1 ± 6.7 6.8 ± 7.3 
Duration of OAD treatment (years) 7.4 ± 5.4 8.0 ± 5.2 
HbA1c level (%)   
    Baseline 8.8 ± 1.1 8.7 ± 1.1 
    End point 7.8 ± 1.3 7.7 ± 1.2 
Fasting plasma glucose level (mg/dl [mmol/l])   
    Baseline 199 ± 2 [11 ± 0.1] 199 ± 2 [11 ± 0.1] 
    End point 155 ± 2 [8 ± 0.1] 161 ± 2 [9 ± 0.0] 
Insulin glargineNPH insulin
Sex   
    Men 636 (56) 652 (56) 
    Women 506 (44) 510 (44) 
Age (years) 58.0 ± 9.8 58.4 ± 9.3 
BMI (kg/m230.5 ± 4.9 30.5 ± 6.4 
Age at onset of diabetes (years) 48.4 ± 9.7 48.4 ± 9.7 
Diabetes duration (years) 10.2 ± 7.0 10.6 ± 6.9 
Type of previous treatment   
    OAD only 815 (71) 826 (71) 
    Insulin only 259 (23) 259 (22) 
Duration of insulin treatment (years)* 7.1 ± 6.7 6.8 ± 7.3 
Duration of OAD treatment (years) 7.4 ± 5.4 8.0 ± 5.2 
HbA1c level (%)   
    Baseline 8.8 ± 1.1 8.7 ± 1.1 
    End point 7.8 ± 1.3 7.7 ± 1.2 
Fasting plasma glucose level (mg/dl [mmol/l])   
    Baseline 199 ± 2 [11 ± 0.1] 199 ± 2 [11 ± 0.1] 
    End point 155 ± 2 [8 ± 0.1] 161 ± 2 [9 ± 0.0] 

Data are means ± SD or n (%).

*

Only patients in study 3006 (100%) and study 3002 (25%) were on insulin prior to study initiation.

P = 0.0233 for the insulin glargine versus NPH insulin group at end point. OAD, oral antidiabetic agent.

Close Modal

or Create an Account

Close Modal
Close Modal